TY - JOUR
T1 - Inhibition of dipeptidyl peptidase-4
T2 - The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes
AU - Smushkin, Galina
AU - Vella, Adrian
PY - 2009
Y1 - 2009
N2 - Postprandial hyperglycemia in type 2 diabetes is characterized by impaired insulin secretion and action, decreased glucose effectiveness and defective suppression of glucagon secretion. Newly available therapies for type 2 diabetes target the pathway of the incretin hormone glucagon-like peptide-1 (GLP-1). Oral inhibitors of dipeptidyl peptidase-4 (DPP-4) raise the level of endogenous GLP-1 by inhibiting its clearance thereby lowering fasting and postprandial glucose concentrations. Unlike compounds which act as agonists of the GLP-1 receptor, DPP-4 inhibitors are not associated with significant effects on gastrointestinal motility, which led to a controversy around the mechanisms responsible for their glucose-lowering effects. Here we review the evidence in regards to the mechanisms whereby DPP-4 inhibitors lower glucose concentrations. Their effects are most likely mediated by an increase in endogenous GLP-1, although additional mechanisms may be involved. The pharmacology, efficacy and safety of vildagliptin, a novel DPP-4 inhibitor, are also discussed.
AB - Postprandial hyperglycemia in type 2 diabetes is characterized by impaired insulin secretion and action, decreased glucose effectiveness and defective suppression of glucagon secretion. Newly available therapies for type 2 diabetes target the pathway of the incretin hormone glucagon-like peptide-1 (GLP-1). Oral inhibitors of dipeptidyl peptidase-4 (DPP-4) raise the level of endogenous GLP-1 by inhibiting its clearance thereby lowering fasting and postprandial glucose concentrations. Unlike compounds which act as agonists of the GLP-1 receptor, DPP-4 inhibitors are not associated with significant effects on gastrointestinal motility, which led to a controversy around the mechanisms responsible for their glucose-lowering effects. Here we review the evidence in regards to the mechanisms whereby DPP-4 inhibitors lower glucose concentrations. Their effects are most likely mediated by an increase in endogenous GLP-1, although additional mechanisms may be involved. The pharmacology, efficacy and safety of vildagliptin, a novel DPP-4 inhibitor, are also discussed.
KW - DPP-4 inhibitor
KW - Glucagon-like peptide 1
KW - Incretin
KW - Insulin action
KW - Insulin secretion
UR - http://www.scopus.com/inward/record.url?scp=77953443578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953443578&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:77953443578
SN - 1178-7007
VL - 2
SP - 83
EP - 90
JO - Diabetes, Metabolic Syndrome and Obesity
JF - Diabetes, Metabolic Syndrome and Obesity
ER -